LIHUA CHEN^1,2,#, HONGTIAN ZHANG^1,2,#, YONG XIA^1,2, KAI SUN¹, WENJIN CHEN¹, RUXIANG XU^1,2,*

BIOCELL, Vol.47, No.5, pp. 1065-1073, 2023, DOI:10.32604/biocell.2023.025924 - 10 April 2023

Abstract Purpose: The present study summarized cases of children (n = 32) with medulloblastoma (MB) who were treated using stratified therapy based on risk grading and also discussed the factors affecting prognosis. Methods: According to the risk stratification criteria, the cases were divided into the following four risk groups: low, standard, high, and very high. The 5-year overall survival (OS) and progression-free survival (PFS) rates were summarized. Further, the effects on the prognosis of tumor size, tumor stage, degree of resection, treatment mode, metastatic recurrence, molecular typing, and risk stratification were analyzed. Results: In the present study, following… More >

Yi Chen^1,#, Liyun Huang^1,#, Zuwu Wei¹, Xiaoling Liu¹, Lihong Chen^1,2,*, Bin Wang^1,2,*

Oncologie, Vol.24, No.2, pp. 329-340, 2022, DOI:10.32604/oncologie.2022.022521 - 29 June 2022

Abstract Background: The effective method for predicting prognosis of ICC is still lack. This study aims to establish and verify an effective prognostic nomogram model for intrahepatic cholangiocarcinoma (ICC) after partial hepatectomy. Materials and Methods: A nomogram model was developed in a cohort of 127 patients from January 2015 to December 2019. General clinical characteristics including preoperative physical examination data and postoperative pathological features were obtained. The independent risk factors identified by univariate and multivariate COX proportional hazards regression models were used to construct nomogram model. Predictive accuracy and discriminative ability were determined using a concordance index and… More >

Junhui Sun^*1, Guanhui Zhou^*1, Xiaoxi Xie^†, Wenjiang Gu^‡, Jing Huang^§, Dedong Zhu^¶, Wenhao Hu^#, Qinming Hou^**, Changsheng Shi^††, Tiefeng Li^‡‡ , Xin Zhang^§§, Wenbin Ji^¶¶, Shihong Ying^§§, Zhiyi Peng^§§, Jian Zhou^##, Zhihai Yu^***, Jiansong Ji^†††, Haijun Du^‡‡‡, Xiaohua Guo^§§§, Jian Fang^¶¶¶, Jun Han^###, Huanhai Xu^****, Zhichao Sun^††††, Wenqiang Yu^‡‡‡‡, Guoliang Shao^§§§§, Xia Wu^¶¶¶¶ ,Hongjie Hu^¶¶¶¶ , Ling Li^#, Jiaping Zheng^§§§§, Jun Luo^§§§§, Yutang Chen^§§§§, Guohong Cao^####, Tingyang Hu^‡‡‡‡

Oncology Research, Vol.28, No.1, pp. 75-94, 2020, DOI:10.3727/096504019X15662966719585

Abstract The purpose of this study was to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Chinese hepatocellular carcinoma (HCC) patients and the prognostic factors for treatment response as well as survival. A total of 275 HCC patients were included in this prospective study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST), and progression-free survival (PFS) as well as overall survival (OS) were determined. Liver function and adverse events (AEs) were assessed before and after DEB-TACE operation. Complete response (CR), partial response (PR), and objective response… More >

Arisha Patel, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Melissa Saul, Daniel Normolle, Konstantinos Lontos, Michael Boyiadzis

Oncology Research, Vol.28, No.7-8, pp. 811-814, 2020, DOI:10.3727/096504020X15965357399750

Abstract Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with late relapse at our institution and reviewed the literature for these patients. The study cohort consisted of nine AML patients with late relapse. The median interval between CR1 and AML relapse was 6.1 years (range: 5.1–16.2 years). At relapse, the karyotype was different from the initial AML diagnosis in 50% of patients. At the time of AML relapse, seven patients received induction chemotherapy and two More >

Chuanwei Xu¹, Renju Ding², Chuanping Xu^3,*

Oncologie, Vol.22, No.1, pp. 43-51, 2020, DOI:10.32604/oncologie.2020.012445

Abstract To analyze the effects of different surgical procedures for the treatment of thyroid cancer on the expression levels of serum interleukin-17 (IL-17), IL-35, soluble interleukin-2 receptor (SIL-2R), and the prognostic factors. Seventy-eight patients with differentiated thyroid cancer were selected and grouped as control group (CG) (n = 39, underwent subtotal thyroidectomy) and observation group (OG) (n = 39, underwent total thyroidectomy). The serum IL-17, IL-35, and SIL- 2R expression levels; the incidence of complications; and the differentiated thyroid carcinoma (DTC) relapse rate were compared between the two groups. The serum IL-17 and SIL-2R levels were… More >

Annie Im, Ali Amjad, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Seah Lim, Alison Sehgal, Kathleen A. Dorritie, Robert L. Redner, Brian McLaughlin, Yongli Shuai, Shrina Duggal, Michael Boyiadzis

Oncology Research, Vol.24, No.2, pp. 73-80, 2016, DOI:10.3727/096504016X14586627440156

Abstract Relapsed acute myeloid leukemia (AML) represents a major therapeutic challenge. Achieving complete remission (CR) with salvage chemotherapy is the first goal of therapy for relapsed AML. However, there is no standard salvage chemotherapy. The current study evaluated outcomes and prognostic factors for achievement of CR in 91 AML patients in first relapse who were treated with the mitoxantrone–etoposide combination regimen. The overall response rate (CR and CRi) was 25%. Factors that were associated with a lower rate of CR included older age, shorter duration of first CR, low hemoglobin, and low platelet count. The median… More >